Chemed (CHE)
(Delayed Data from NYSE)
$587.39 USD
+9.62 (1.67%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $587.22 -0.17 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$587.39 USD
+9.62 (1.67%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $587.22 -0.17 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Zacks News
Here's Why Investors Should Hold Ensign Group (ENSG) Stock Now
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth on the back of a growing revenue base, continuous pursuit of acquisitions and commendable financial position.
PNTG vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PNTG vs. CHE: Which Stock Is the Better Value Option?
Zacks Industry Outlook Highlights Chemed, Addus HomeCare, RadNet and The Pennant Group
by Zacks Equity Research
Chemed, Addus HomeCare, RadNet and The Pennant Group are part of the Zacks Industry Outlook article.
4 Promising Stocks From a Challenging Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. CHE, ADUS, RDNT and PNTG are well poised to gain from the prospects.
Chemed (CHE) Up on Roto-Rooter Sales Growth, Strong Admissions
by Zacks Equity Research
Chemed (CHE) records increases in drain cleaning, plumbing, excavation and water restoration revenues within the Roto-Rooter branch commercial business.
Is Bellicum Pharmaceuticals (BLCM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Bellicum Pharmaceuticals (BLCM) and Chemed (CHE) have performed compared to their sector so far this year.
PNTG or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PNTG vs. CHE: Which Stock Is the Better Value Option?
PNTG vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
PNTG vs. CHE: Which Stock Is the Better Value Option?
Chemed (CHE) Q4 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Chemed (CHE) reports impressive sales growth in the Roto-Rooter subsidiary in the fourth quarter of 2022.
Chemed (CHE) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 1.70% and 0.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
DaVita HealthCare (DVA) Q4 Earnings Beat Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 26.14% and 0.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
PNTG or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PNTG vs. CHE: Which Stock Is the Better Value Option?
PNTG vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
PNTG vs. CHE: Which Stock Is the Better Value Option?
Chemed (CHE) Q3 Earnings Surpass Estimates, EPS View Up
by Zacks Equity Research
Chemed's (CHE) full-year VITAS revenues, prior to Medicare Cap, are once again estimated to decline.
Chemed (CHE) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 2.82% and 1.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Chemed (CHE) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Chemed (CHE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Earnings Preview: Chemed (CHE) Q3 Earnings Expected to Decline
by Zacks Equity Research
Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Chemed (CHE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Chemed (CHE) stock based on the movements in the options market lately.
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors are optimistic about Chemed's (CHE) Roto-Rooter business, which is witnessing continued demand for plumbing, drain cleaning services and water restoration services.
Option Care (OPCH) Stock Jumps 8.9%: Will It Continue to Soar?
by Zacks Equity Research
Option Care (OPCH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Chemed (CHE) Roto-Rooter Business Grows, VITAS Admission Dips
by Zacks Equity Research
The performance of Chemed's (CHE) VITAS business is somewhat offset by a geographically weighted average Medicare reimbursement rate increase.
Chemed's (CHE) Roto-Rooter Growth Aids, Macro Challenges Ail
by Zacks Equity Research
Chemed's (CHE) VITAS segment revenue decline during the second quarter gets somewhat offset by a geographically weighted average Medicare reimbursement rate increase of nearly 1.3%.
Here's Why You Should Hold on to Chemed (CHE) Stock Now
by Zacks Equity Research
Investors are optimistic about Chemed's (CHE) better-than-expected earnings and impressive Roto-Rooter results.
PNTG vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PNTG vs. CHE: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights H&R Block, Chemed, Suncor Energy, Open Text and Essent Group
by Zacks Equity Research
H&R Block, Chemed, Suncor Energy, Open Text and Essent Group are part of the Zacks top Analyst Blog.